Ventus Therapeutics U.S., Inc. — Form D
Ventus Therapeutics U.S., Inc. of WALTHAM, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-04-14. The offering totals $100.0M, of which $100.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-04-14
- Form: D
- Accession: 0001841613-21-000004
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $100.0M
- Investors: 17
- Date of first sale: 2021-03-31
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-395752
Issuer
- Name: Ventus Therapeutics U.S., Inc.
- CIK: 0001794785
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 100 BEAVER STREET, SUITE 202, WALTHAM, MA, 02453
- Phone: 514-397-9517
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Steven James | Director | REDWOOD CITY, CA |
| John Cassidy | Director | Dover, DE |
| Jerel Davis | Director | Alameda, CA |
| Brendan Bulik-Sullivan | Director | Alameda, CA |
| Hao Wu | Director | Piedmont, SC |
| Daniel Koerwer | Executive Officer | Walthum, MA |
| Josh Resnick | Director | Walthum, MA |
| Markus Warmuth | Director | c/o Ventus Therapeutics U.S.,, MA |
| Michael Crackower | Executive Officer | Waltham, MA |
| Jane Pritchett Henderson | Director | Walthum, MA |
| Marcelo Bigal | Director | Walthum, MA |
| Marcelo Bigal | Executive Officer | Walthum, MA |
| Dolca Thomas | Director | Walthum, MA |
| Zachary McNealy | Executive Officer | Walthum, MA |
Other filings by this issuer (2)
More